<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169681">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887757</url>
  </required_header>
  <id_info>
    <org_study_id>M10-588</org_study_id>
    <nct_id>NCT00887757</nct_id>
  </id_info>
  <brief_title>Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Gemzar® (Gemcitabine) in the Treatment of Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when
      combined with a standard regimen of gemcitabine in approximately 50 subjects with solid
      tumors and measurable disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety profile of ABT-263 in combination with gemcitabine.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study the pharmacokinetic interaction between ABT-263 and gemcitabine.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of ABT-263 in combination with gemcitabine.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule in combination with a standard and weekly regimen of gemcitabine.</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding progression free survival (PFS)</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding objective response rate (ORR)</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding time to tumor progression (TTP)</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding overall survival (OS)</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding duration of overall response</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data with Eastern Cooperative Oncology Group (ECOG) performance status</measure>
    <time_frame>Bi-monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate biomarkers to</measure>
    <time_frame>Bi-monthly</time_frame>
    <description>Define the relationship between disease states, B-Cell Lymphoma 2 (Bcl-2) family protein expression, and potential response to the proposed therapy navitoclax when added to a standard and weekly regimen of gemcitabine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>gemcitabine +ABT-263</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.
325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.
This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.</description>
    <arm_group_label>gemcitabine +ABT-263</arm_group_label>
    <other_name>navitoclax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.</description>
    <arm_group_label>gemcitabine +ABT-263</arm_group_label>
    <other_name>gemzar, gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age greater then or equal to 18 years.

          -  For the 21 and 28-day dose escalation cohorts and the 21-day safety expansion cohort
             subjects must have histologically and/or cytologically documented cancer for which
             gemcitabine has been determined to be an appropriate therapy, per the Investigator.

          -  For the 28-day safety expansion cohort, subjects must have histologically and/or
             cytologically documented ductal adenocarcinoma or undifferentiated carcinoma of the
             pancreas for which gemcitabine has been determined to be an appropriate first-line
             therapy, per the investigator.

        Note: If the 28-day dose escalation schedule is deemed intolerable and further dose
        de-escalation is not explored, the expanded safety cohort will evaluate navitoclax
        (ABT-263) in combination with gemcitabine in an additional 12 to 15 subjects with
        histologically ductal adenocarcinoma or undifferentiated carcinoma of the pancreas for
        which gemcitabine has been determined to be an appropriate first-line therapy with the
        RPTD and schedule from the 21-day portion of the study.

          -  Measurable disease by CT or MRI as defined RECIST.

          -  Subjects with brain metastases must have clinically controlled neurologic symptoms,
             defined as surgical excision and/or radiation therapy followed by 21 days of stable
             neurologic function and no evidence of CNS disease progression as determined by CT or
             MRI within 28 days prior to the 1st dose of study drug.

          -  ECOG less then or equal to 1.

          -  Must have adequate bone marrow, renal and hepatic function per local laboratory
             reference range as follows:

               -  Bone marrow:Absolute Neutrophil Count greater then or equal to1500/μL; platelets
                  greater then or equal to 150,000/mm^3; hemoglobin greater then or equal to 9.0
                  g/dL;

               -  Renal function: Serum creatinine less then or equal to 2.0 mg/dL or calculated
                  creatinine clearance greater then or equal to 50 mL/min;

               -  Hepatic function and enzymes: AST , ALP and ALT less then or equal to 3.0 × the
                  upper limit of normal (ULN), bilirubin less then or equal to 1.5 × ULN.

               -  Subjects with liver metastasis may have AST, ALP, and ALT less then or equal to
                  5.0 X ULN.

               -  Subjects with bone metastasis may have ALP less then or equal to 5.0 × ULN;
                  Coagulation: aPTT and PT not to exceed 1.2 × ULN.

          -  Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or
             have negative results for a pregnancy test performed as follows: at Screening via
             serum sample obtained within 14 days prior to initial study drug administration and
             prior to dosing via urine sample obtained on Cycle 1 Day 1, if it has been greater
             then 7 days since obtaining the serum pregnancy test results.

          -  Female subjects not surgically sterile or postmenopausal (for at least 1 year) and
             non-vasectomized male subjects must practice at least 1 of the following methods of
             birth control:

               -  total abstinence from sexual intercourse (minimum 1 complete menstrual cycle);

               -  vasectomized partner;

               -  hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months
                  prior to study drug administration;

               -  Double-barrier method (including condoms, contraceptive sponge, diaphragm or
                  vaginal ring with spermicidal jellies or cream).

        Exclusion Criteria

          -  Underlying, predisposing condition of bleeding or currently exhibits signs of
             bleeding.

          -  Recent history of thrombocytopenia associated with bleeding w/i 1 year prior to 1st
             dose of study drug.

          -  Currently receiving or requires anticoagulation therapy or any drugs or herbal
             supplements that affect platelet function, w/the exception of low-dose
             anticoagulation medications that are used to maintain the patency of a central iv
             catheter.

          -  Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.

          -  Active immune thrombocytopenic purpura, autoimmune hemolytic anemia or a history of
             being refractory to platelet transfusions (w/i 1 year prior to the 1st dose of study
             drug).

          -  Received radio-immunotherapy w/i 6 months prior to 1st dose of study drug.

          -  Received an antibody therapy or other biologics (with the exception of colony
             stimulating factors [G-CSF,GM-CSF] or erythropoietin) w/i 28 days prior to 1st dose
             of study drug.

          -  Received anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy,
             hormonal therapy (with the exception of hormones for hypothyroidism, ERT,
             anti-estrogen analogs, LHRH, GnRH agonists required to suppress serum testosterone
             levels if on a stable dose for at least 21 days prior to the 1st dose of study drug),
             or any investigational therapy w/i 14 days prior to the 1st dose of study drug, or
             has not recovered to less than a grade 2 clinically significant adverse effect(s)/
             toxicity(s) of the previous therapy.

          -  Received steroid therapy for anti-neoplastic intent w/i 7 days prior to the 1st dose
             of study drug. (Inhaled steroids for asthma, topical steroids, replacement/stress
             corticosteroids, or corticosteroids taken as premedication for this study will not be
             considered exclusionary).

          -  Received aspirin w/i 7 days prior to 1st dose of study drug.

          -  History of hypersensitivity to gemcitabine.Positive for HIV.

          -  Significant history of cardiac, renal, neurologic, psychiatric, endocrinologic,
             metabolic, immunologic, or hepatic disease.

          -  Exhibits evidence of other clinically significant uncontrolled condition; active
             systemic fungal infection;diagnosis of fever &amp; neutropenia w/i 1 week prior to study
             drug administration.

          -  The subject has undergone prior procedures or has active gastrointestinal disease
             that would result in the inability to adequately absorb an oral medication (e.g.,
             uncontrolled nausea, vomiting, inflammatory disease, bowel obstruction, or a major
             bowel resection).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mack Mabry, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12847</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 25542</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27364</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27365</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12846</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 21, 2011</lastchanged_date>
  <firstreceived_date>April 23, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
